February 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Dario Tuccinardi on Obesity as Cardiovascular Treatment Target

Dario Tuccinardi/LinkedIn

Jan 20, 2026, 12:33

Dario Tuccinardi on Obesity as Cardiovascular Treatment Target

Dario Tuccinardi, Assistant Professor in Endocrinology at The Bio-Medical University of Rome, shared on LinkedIn:

”Obesity is no longer just a cardiovascular risk factor. It is a cardiovascular treatment target.

Obesity and visceral adiposity actively shape cardiovascular disease, through inflammation, altered myocardial energetics, and diagnostic distortion.

Yet in daily practice, patients with obesity are still affected by clinical bias: symptoms are under-recognized, biomarkers misinterpreted, and treatment decisions delayed or diluted.

Our review argues for a double shift.

First: therapeutic.
Modern anti-obesity pharmacotherapy, especially GLP-1 receptor agonists and dual-incretin agents, extends beyond weight loss.

These drugs improve endothelial function, reduce inflammation, optimize myocardial metabolism, and now demonstrate cardiovascular event reduction even in people with obesity without diabetes.

Second: cultural and clinical.
Cardiologists must be supported in overcoming weight-related bias—moving beyond BMI, recognizing visceral obesity, correctly interpreting biomarkers, and confidently treating obesity as part of cardiovascular care rather than deferring it.

Treating obesity is no longer optional.

It is evidence-based cardiovascular medicine.

Weight loss is not about weight.

It’s about outcomes.”

Dario Tuccinardi on Obesity as Cardiovascular Treatment Target